These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 28498352)

  • 41. Enteroinsular axis of db/db mice and efficacy of dipeptidyl peptidase IV inhibition.
    Nagakura T; Yasuda N; Yamazaki K; Ikuta H; Tanaka I
    Metabolism; 2003 Jan; 52(1):81-6. PubMed ID: 12524666
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Emerging role of dipeptidyl peptidase-IV (DPP-4) inhibitor vildagliptin in the management of type 2 diabetes.
    Kalra S
    J Assoc Physicians India; 2011 Apr; 59():237-45. PubMed ID: 21755761
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Stimulation of intestinal growth and function with DPP4 inhibition in a mouse short bowel syndrome model.
    Sueyoshi R; Woods Ignatoski KM; Okawada M; Hartmann B; Holst J; Teitelbaum DH
    Am J Physiol Gastrointest Liver Physiol; 2014 Aug; 307(4):G410-9. PubMed ID: 24970775
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Natural phenolic compounds potentiate hypoglycemia via inhibition of Dipeptidyl peptidase IV.
    Huang PK; Lin SR; Chang CH; Tsai MJ; Lee DN; Weng CF
    Sci Rep; 2019 Oct; 9(1):15585. PubMed ID: 31666589
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Fixed-Dose Combination of Dapagliflozin + Sitagliptin + Metformin in Patients with Type 2 Diabetes Poorly Controlled with Metformin: Phase 3, Randomized Comparison with Dual Combinations.
    Sahay RK; Giri R; Shembalkar JV; Gupta SK; Mohan B; Kurmi P; Kumar SR; Sawardekar VM; Mishra A; Murthy LS; Arya VV; Sonawane AR; Soni PN; Gofne SK; Karnawat SR; Rajurkar MN; Patel PM; Lakhwani LK; Mehta SC; Joglekar SJ
    Adv Ther; 2023 Jul; 40(7):3227-3246. PubMed ID: 37258803
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Role of DPP4 and DPP4i in Glucose Homeostasis and Cardiorenal Syndrome.
    Panda SP
    Endocr Metab Immune Disord Drug Targets; 2023; 23(2):179-187. PubMed ID: 35642117
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Modified mesoporous silica nanoparticles for enhancing oral bioavailability and antihypertensive activity of poorly water soluble valsartan.
    Biswas N
    Eur J Pharm Sci; 2017 Mar; 99():152-160. PubMed ID: 27993684
    [TBL] [Abstract][Full Text] [Related]  

  • 48. DPP4 in cardiometabolic disease: recent insights from the laboratory and clinical trials of DPP4 inhibition.
    Zhong J; Maiseyeu A; Davis SN; Rajagopalan S
    Circ Res; 2015 Apr; 116(8):1491-504. PubMed ID: 25858071
    [TBL] [Abstract][Full Text] [Related]  

  • 49. An emerging role of dipeptidyl peptidase 4 (DPP4) beyond glucose control: potential implications in cardiovascular disease.
    Zhong J; Rao X; Rajagopalan S
    Atherosclerosis; 2013 Feb; 226(2):305-14. PubMed ID: 23083681
    [TBL] [Abstract][Full Text] [Related]  

  • 50. pH responsive cylindrical MSN for oral delivery of insulin-design, fabrication and evaluation.
    Guha A; Biswas N; Bhattacharjee K; Sahoo N; Kuotsu K
    Drug Deliv; 2016 Nov; 23(9):3552-3561. PubMed ID: 27540687
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Combined treatment with dipeptidyl peptidase 4 (DPP4) inhibitor sitagliptin and elemental diets reduced indomethacin-induced intestinal injury in rats via the increase of mucosal glucagon-like peptide-2 concentration.
    Fujiwara K; Inoue T; Yorifuji N; Iguchi M; Sakanaka T; Narabayashi K; Kakimoto K; Nouda S; Okada T; Ishida K; Abe Y; Masuda D; Takeuchi T; Fukunishi S; Umegaki E; Akiba Y; Kaunitz JD; Higuchi K
    J Clin Biochem Nutr; 2015 Mar; 56(2):155-62. PubMed ID: 25759522
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of boschnaloside from Boschniakia rossica on dysglycemia and islet dysfunction in severely diabetic mice through modulating the action of glucagon-like peptide-1.
    Lin LC; Lee LC; Huang C; Chen CT; Song JS; Shiao YJ; Liu HK
    Phytomedicine; 2019 Sep; 62():152946. PubMed ID: 31102890
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical and Physiological Characterization of Elevated Plasma Glucagon-Like Peptide-1 Levels (Hyperglipemia) in a Dipeptidyl Peptidase IV Mutation Carrier.
    Zhao D; Zhao S; Wang X; Su M; Liu W; Ma Q; Hong J; Gu W; Li J; Liu R; Ning G; Wang J; Zhang Y
    Front Endocrinol (Lausanne); 2018; 9():62. PubMed ID: 29556215
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dipeptidyl-peptidase 4 inhibition and the vascular effects of glucagon-like peptide-1 and brain natriuretic peptide in the human forearm.
    Devin JK; Pretorius M; Nian H; Yu C; Billings FT; Brown NJ
    J Am Heart Assoc; 2014 Aug; 3(4):. PubMed ID: 25158865
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta-analysis.
    Min SH; Yoon JH; Hahn S; Cho YM
    Diabetes Metab Res Rev; 2017 Jan; 33(1):. PubMed ID: 27155214
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The effect of combined treatment with canagliflozin and teneligliptin on glucose intolerance in Zucker diabetic fatty rats.
    Oguma T; Kuriyama C; Nakayama K; Matsushita Y; Yoshida K; Kiuchi S; Ikenaga Y; Nakamaru Y; Hikida K; Saito A; Arakawa K; Oka K; Ueta K; Shiotani M
    J Pharmacol Sci; 2015 Apr; 127(4):456-61. PubMed ID: 25892328
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The impact of dipeptidyl peptidase 4 inhibition on incretin effect, glucose tolerance, and gastrointestinal-mediated glucose disposal in healthy subjects.
    Rhee NA; Østoft SH; Holst JJ; Deacon CF; Vilsbøll T; Knop FK
    Eur J Endocrinol; 2014 Sep; 171(3):353-62. PubMed ID: 24935932
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Exploring mesoporous silica nanoparticles as oral insulin carriers:
    Salarkia E; Mehdipoor M; Molaakbari E; Khosravi A; Sazegar MR; Salari Z; Rad I; Dabiri S; Joukar S; Sharifi I; Ren G
    Heliyon; 2023 Oct; 9(10):e20430. PubMed ID: 37810809
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A siRNA mediated hepatic dpp4 knockdown affects lipid, but not glucose metabolism in diabetic mice.
    Görgens SW; Jahn-Hofmann K; Bangari D; Cummings S; Metz-Weidmann C; Schwahn U; Wohlfart P; Schäfer M; Bielohuby M
    PLoS One; 2019; 14(12):e0225835. PubMed ID: 31794591
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Altered dipeptidyl peptidase-4 activity during the progression of hyperinsulinemic obesity and islet atrophy in spontaneously late-stage type 2 diabetic rats.
    Kirino Y; Sato Y; Kamimoto T; Kawazoe K; Minakuchi K
    Am J Physiol Endocrinol Metab; 2011 Feb; 300(2):E372-9. PubMed ID: 21139073
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.